Product
AK104+Axitinib
1 clinical trial
3 indications
Indication
MelanomaIndication
Mucosal melanomaIndication
Metastatic MelanomaClinical trial
A Phase Ib, Open, Mono-center, Dose-reduction Tolerability Study of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaStatus: Not yet recruiting, Estimated PCD: 2025-12-31